Denali Therapeutics Net Income 2011-2026 | DNLI

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Denali Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-423 M	-145 M	-326 M	-291 M	71.1 M	-198 M	-36.2 M	-88.2 M	-86.7 M	-16.8 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
71.1 M	-423 M	-154 M

Quarterly Net Income Denali Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-127 M	-124 M	-133 M	-	-107 M	-99 M	-102 M	-	-99.4 M	183 M	-110 M	-	-103 M	-58.8 M	-65.2 M	-	-84.6 M	-60.7 M	-70 M	-	-58.2 M	-58.8 M	-56.8 M	-54 M	-46.3 M	-58.3 M	-39 M	77.5 M	-35.4 M	-54.7 M	-23.7 M	-22.9 M	-21.8 M	-22.1 M	-21.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
183 M	-133 M	-55.2 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Xeris Pharmaceuticals XERS	554 K	$ 6.03	-1.55 %	$ 885 M	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
UroGen Pharma Ltd. URGN	-153 M	$ 19.2	-11.52 %	$ 554 M	Israel
uniQure N.V. QURE	-199 M	$ 10.89	-30.36 %	$ 530 M	Niderland
GT Biopharma GTBP	-28.4 M	$ 0.47	-2.41 %	$ 892 K	USA
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
AbCellera Biologics ABCL	-146 M	$ 3.74	3.6 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-14.7 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	-257 M	$ 3.36	0.86 %	$ 1.2 M	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	-413 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Завод ДИОД DIOD	37.2 M	-	-	-	Russia
Фармсинтез LIFE	-525 M	-	-	-	Russia
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	-143 M	$ 2.19	-9.77 %	$ 226 M	USA
Entera Bio Ltd. ENTX	-9.98 M	$ 1.38	-0.72 %	$ 63.3 M	Israel
Allena Pharmaceuticals ALNA	-48.7 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-62.9 M	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	-95.1 M	$ 4.21	-2.32 %	$ 299 M	USA
Teligent, Inc. TLGT	-25.1 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	-58.8 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	-30.4 M	$ 0.84	-4.24 %	$ 27.9 M	Israel
Viela Bio, Inc. VIE	-151 M	-	-	$ 2.91 B	USA
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	-38.8 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AbbVie ABBV	1.82 B	$ 233.57	0.64 %	$ 413 B	USA
Blueprint Medicines Corporation BPMC	-67.1 M	-	-	$ 8.14 B	USA
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
AIM ImmunoTech AIM	-19.4 M	$ 0.8	-11.6 %	$ 38.5 M	USA
Aptorum Group Limited APM	-4.27 M	$ 0.83	5.37 %	$ 4.53 M	China
Apellis Pharmaceuticals APLS	22.4 M	$ 20.67	-1.38 %	$ 2.61 B	USA